KINE 2475 Lecture Notes - Lecture 32: Botulinum Toxin, Myosin Light-Chain Kinase, Sympathetic Nervous System
18 Jan 2021
School
Department
Course
Professor
Document Summary
Syndrome: antimuscarinic drugs, mirabegron - b3 antagonist, onabotulinumotoxin (botulinum toxin) Drugs in treatment of bph: a1 adrenergic receptor antagonist, 5a-reductive inhibitors. Learning objectives: mechanisms of action & connection with condition. Apple mechanism of action and its use in solving the condition. Autonomic system review: these receptors for parasympathetic, off target effects of anti-muscarinic drugs, off-target effects could be rationally concluded. A1 adrenergic receptor antagonist: a1 receptors blockers. Pharmacotherapy of oab: detrusor muscle of bladder, this muscle is responsible for oab. Antimuscarinic drugs: muscarinic receptors everywhere in body, oxybutyin has effects on other effects on muscarinic. It can cross bbb, to have effect on brain. Transdermal has reduced effect: tolterodine- is more selective for muscarinic in bladdder, few effects in brain. Thus keep in mind when dosing multiple drugs: trospium- it has charged, limited entry to cns. Potential for drug interactions: daifenacin- antimuscarinic, propiverine- also a ccb, important for drug interaction.
